EGFR and non-small cell lung carcinoma: Osimertinib has been approved for patients with metastatic NSCLC tested positive for the EGFR p.T790M mutation, occurring during disease progression or after EGFR-TKI therapy, when additional tissue biopsy is not always achievable without risk.